INCR (Intercure) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCR Intercure Ltd INCR
69 GF Score
Price $5.31
GF Value $5.74
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Intercure Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

INCR
69GF Score
Intercure Ltd INCR
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Intercure (INCR) Overvalued in 2026?

Based on GuruFocus' analysis, Intercure stock appears to be undervalued. The current stock price of $5.31 is trading 7.5% below its estimated GF Value™ of $5.74. GuruFocus considers Intercure to be Fairly Valued.

Key valuation signals for INCR:

  • Interest Expense (Positive):
  • GF Value™: $5.74 vs. price of $5.31 (7.5% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intercure Business Description

Other Exchanges INCR:Israel
Address 85 Medinat ha-Yehudim Street, Herzliya, ISR, 4676670
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
69GF Score

Get the complete analysis for INCR

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.31
Price
$5.74
GF Value